Therapy of Hypoparathyroidism With PTH(1–84): A Prospective Six Year Investigation of Efficacy and Safety | Zendy

Mishaela R. Rubin | Zendy; Natalie E. Cusano | Zendy; Wen-Wei Fan | Zendy; Yasmine Delgado | Zendy; Chengchen Zhang | Zendy; Aline G. Costa | Zendy; Serge Cremers | Zendy; Elzbieta Dworakowski | Zendy; John P. Bilezikian | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Therapy of Hypoparathyroidism With PTH(1–84): A Prospective Six Year Investigation of Efficacy and Safety

Author(s) -

Mishaela R. Rubin,

Natalie E. Cusano,

Wen-Wei Fan,

Yasmine Delgado,

Chengchen Zhang,

Aline G. Costa,

Serge Cremers,

Elzbieta Dworakowski,

John P. Bilezikian

Publication year - 2016

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2015-4135

Subject(s) - hypoparathyroidism , medicine , urinary calcium , bone remodeling , regimen , calcium , urology , endocrinology , vitamin d and neurology , teriparatide , parathyroid hormone , parathyroid gland , bone mineral , osteoporosis

Human recombinant (rh)PTH(1-84) was recently approved for the treatment of refractory hypoparathyroidism, based upon a short-term phase 3 clinical trial. Long-term data are needed, because no time limit was placed on the treatment period.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research